H.R. 4716 would amend the Internal Revenue Code to allow a high deductible plan to provide inhalers for treatment of any chronic lung disease, or any medicine or drug which is delivered through such inhaler for treatment of such disease, without a deductible and without affecting a beneficiary’s eligibility to participate in a Health Savings Account (HSA).
Estimated budgetary effects would primarily stem from
An increase in contributions to HSAs, which are excluded from income and employment taxes
The Congressional Budget Act of 1974, as amended, stipulates that revenue estimates provided by the staff of the Joint Committee on Taxation (JCT) will be the official estimates for all tax legislation considered by Congress. As such, CBO incorporates those estimates into its cost estimates of the effects of legislation. All of the estimates for the provisions of H.R. 4716 were provided by JCT.